Assessing the clinical relevance of drug-drug interactions (DDI) with darolutamide (DARO)
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz248.047
Abstract: Abstract Background DARO is an androgen receptor antagonist with a distinct molecular structure, which has demonstrated prolonged metastasis-free survival vs placebo (PBO) in the phase 3 ARAMIS study in non-metastatic castration-resistant prostate cancer patients. These… read more here.
Keywords: consultancy; research grant; bayer; honoraria self ... See more keywords
Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC).
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.5000
Abstract: 5000 Background: DARO is a structurally distinct androgen receptor antagonist for which in vitro and phase 1/2 studies suggest low risk of adverse events (AEs) and drug–drug interaction. In the ARAMIS study of DARO in… read more here.
Keywords: qol; pain; prostate cancer; pbo ... See more keywords
Post-progression survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC) who received darolutamide or placebo: Post hoc analysis of ARASENS.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.5083
Abstract: 5083 Background: Darolutamide (DARO) is a structurally distinct and highly potent androgen receptor pathway inhibitor (ARPI). In ARASENS (NCT02799602), the addition of DARO to androgen-deprivation therapy (ADT) and docetaxel (DOC) significantly reduced the risk of… read more here.
Keywords: post progression; survival; progression; daro ... See more keywords
Darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC) by disease volume: Subgroup analysis of the phase 3 ARANOTE trial.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.5_suppl.151
Abstract: 151 Background: Darolutamide (DARO) plus ADT significantly reduced the risk of radiological progression or death by 46% (HR 0.54; 95% CI: 0.41–0.71; P read more here.
Keywords: disease; progression; adt; daro ... See more keywords
Real-world use and outcomes of darolutamide (DARO), enzalutamide (ENZA), and apalutamide (APA) for nonmetastatic castration-resistant prostate cancer (nmCRPC): Race subgroup analysis.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.5_suppl.158
Abstract: 158 Background: Comparative real-world (RW) data on androgen receptor inhibitor (ARI; DARO, ENZA, APA) use in nmCRPC are limited. DEAR-EXT (NCT06013475) compared the RW utilization, tolerability, and outcomes of all 3 ARIs. Here we present… read more here.
Keywords: treatment; daro; enza apa; race ... See more keywords
Addition of darolutamide to first line treatment of metastatic castration-resistant prostate cancer (mCRPC): A randomized open label phase II trial (SAKK 08/23).
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.5_suppl.tps280
Abstract: TPS280 Background: The implementation of androgen-receptor pathway inhibitors (ARPI) +/- docetaxel (doce) in addition to androgen deprivation therapy (ADT)in metastatic hormone sensitive prostate cancer (mHSPC) has limited the therapeutic options in the mCRPC setting. In… read more here.
Keywords: mcrpc; trial; response; addition ... See more keywords
Efficacy and safety of darolutamide versus abiraterone acetate plus prednisone in combination with ADT for mHSPC: a real-world clinical retrospective study
Sign Up to like & getrecommendations! Published in 2025 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2025.1608339
Abstract: Introduction Effective treatment during the metastatic hormone-sensitive prostate cancer (mHSPC) stage is crucial for delaying disease progression. Due to the lack of a head-to-head comparison of darolutamide (DARO) and abiraterone acetate plus prednisone (AAP) doublet… read more here.
Keywords: time; acetate plus; daro; plus prednisone ... See more keywords